Phenominer Database Results (44 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Time Value Clinical Measurement Notes Record ID Study ID
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 328.0 nmol/l 41.0 123.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107303 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 385.0 nmol/l 89.0 267.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107305 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 6 88.0 % 6.0 14.7 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107073 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 0.08 umol/l 0.02 0.05 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107082 3073
SHRSP/A3NCrl BAY 60-4552-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 110.0 % 2.0 7.48 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107308 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 111.0 % 3.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107093 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 85.0 % 3.0 11.22 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107293 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 67.0 % 6.0 18.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107296 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 460.0 nmol/l 83.0 203.31 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107302 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 93.0 % 8.0 16.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107075 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 0.16 10E-7mol/l 0.03 0.08 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107084 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 0.26 10E-7mol/l 0.1 0.3 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107086 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 0.26 10E-7mol/l 0.15 0.3 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107087 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 103.0 % 9.0 25.46 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107090 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 100.0 % 2.0 6.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107094 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 8 83.0 % 10.0 28.28 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107072 3073
SHRSP/A3NCrl concentration of BAY 60-4552 at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 75.0 nmol/l 16.0 59.87 tissue force analysis utilizing a force transducer 0.0 0 standard rat chow 107306 3073
SHRSP/A3NCrl concentration of GSK2181236A at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 321.0 nmol/l 168.0 475.18 tissue force analysis utilizing a force transducer 0.0 0 high salt high fat diet 107311 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 48.0 % 14.0 28.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107297 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 260.0 nmol/l 74.0 209.3 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107300 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 4 407.0 nmol/l 158.0 316.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107304 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 89.0 % 7.0 21.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107074 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 0.19 10E-7mol/l 0.05 0.15 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107088 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 14 90.0 % 4.0 14.97 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107071 3073
SHRSP/A3NCrl BAY 60-4552-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 111.0 % 2.0 5.66 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107309 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 98.0 % 5.0 12.25 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107091 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 14 0.07 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107077 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 54.0 % 6.0 14.7 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107295 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 8 0.07 umol/l 0.01 0.03 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107078 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (0.3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 4 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 107081 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 0.05 10E-7mol/l 0.01 0.04 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107083 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 108.0 % 4.0 14.97 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107089 3073
SHRSP/A3NCrl phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 91.0 % 8.0 24.0 tissue force analysis utilizing a force transducer 0.0 0 phenylephrine-induced blood vessel contractile force expressed as percent of contractile force generated by potassium chloride (CMO:0003664) 107076 3073
SHRSP/A3NCrl concentration of BAY 60-4552 at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 54.0 nmol/l 14.0 39.6 tissue force analysis utilizing a force transducer 0.0 0 high salt high fat diet 107307 3073
SHRSP/A3NCrl concentration of GSK2181236A at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 270.0 nmol/l 70.0 261.92 tissue force analysis utilizing a force transducer 0.0 0 standard rat chow 107310 3073
SHRSP/A3NCrl GSK2181236A-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 110.0 % 7.0 19.8 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107313 3073
SHRSP/A3NCrl sodium nitroprusside-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 112.0 % 3.0 9.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107092 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 9 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107080 3073
SHRSP/A3NCrl concentration of sodium nitroprusside at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 6 0.25 10E-7mol/l 0.07 0.17 tissue force analysis utilizing a force transducer 0.0 0 nanoMolar 107085 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 8 47.0 % 11.0 31.11 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107294 3073
SHRSP/A3NCrl carbachol-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled BAY60-4552 content diet (3 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 9 59.0 % 4.0 12.0 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107298 3073
SHRSP/A3NCrl concentration of carbachol at which the reduction in force during dilation of a blood vessel is half the maximum value (EC50) control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 119.0 nmol/l 15.0 56.12 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107299 3073
SHRSP/A3NCrl concentration of phenylephrine at which the force of blood vessel contraction is half the maximum value (EC50) controlled sodium chloride content drinking water (1 %) (for 56 days) and controlled fat content diet (24.5 %) (for 56 days) then controlled GSK2181236A content diet (0.1 mg/kg/d) (for 49 days) Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasoconstriction trait male 141 days-148 days 6 0.05 umol/l 0.01 0.02 tissue force analysis utilizing a force transducer 0.0 0 microMolar 107079 3073
SHRSP/A3NCrl GSK2181236A-induced blood vessel dilation expressed as percent reduction of the force generated in a pre-constricted blood vessel control condition Costell MH, etal., Front Pharmacol. 2012 Jul 5;3:128. doi: 10.3389/fphar.2012.00128. eCollection 2012. vasodilation trait male 141 days-148 days 14 110.0 % 3.0 11.22 tissue force analysis utilizing a force transducer 0.0 0 percent reversal of contractile response to 0.3uM phenylephrine 107312 3073